Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer (TURBO): Phase 2, Randomized Controlled Clinical Trial

NCT06518226 is registered in ClinicalTrials.gov with UMC Utrecht as lead sponsor.

NCT NCT06518226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06518226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer (TURBO): Phase 2, Randomized Controlled Clinical Trial
Lead sponsor
UMC Utrecht
Phase
Not applicable
Overall status
Recruiting
Start date
March 28, 2024
Completion date
February 1, 2031
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

localized prostate carcinoma, prostate adenocarcinoma, prostate cancer